What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ensifentrine demonstrated significant short-term efficacy in improving lung function and symptoms in Phase 3 trials, with a notable increase in FEV1 and symptom scores compared to placebo. However, long-term efficacy data beyond one year is lacking, which tempers the overall assessment.
Does the economic case hold at the expected price? — Cost effectiveness
The ICER for ensifentrine is approximately $492,000 per QALY, which is far above acceptable thresholds. This indicates that the therapy is not cost-effective at its current price, posing a significant barrier to its adoption.
Is there quality-of-life evidence payers weigh? — Quality of life
The trials showed significant improvements in HRQoL as measured by the SGRQ, exceeding the minimal clinically important difference. However, the absence of direct utility values limits the assessment of cost-effectiveness.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ensifentrine has a favorable safety profile with low incidence of adverse events compared to placebo. The short-term safety data are robust, and no significant safety signals have emerged in the trials.
Was the drug compared against what payers expect? — Comparator Selection
The use of placebo plus standard of care as a comparator is appropriate for establishing efficacy. However, the lack of active comparator data limits the understanding of how ensifentrine compares to existing therapies.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of moderate to severe COPD patients, and subgroup analyses indicate consistent efficacy across various demographics, including low eosinophil patients.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ensifentrine can be integrated into existing COPD treatment pathways without requiring new diagnostic tests or significant changes in monitoring protocols. However, formal guidelines are still pending.
Are the wider system costs understood? — Resource Use and Cost Implications
The direct costs associated with ensifentrine are high, primarily due to the drug’s price. The potential cost savings from avoided exacerbations do not offset the high annual cost, leading to concerns about budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on two well-conducted Phase 3 RCTs with robust methodologies and consistent results. The trials met their primary and secondary endpoints, providing a strong foundation for the drug’s efficacy.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While the evidence is strong, uncertainties remain regarding long-term efficacy and real-world effectiveness. The potential for inequitable access due to high costs also raises concerns about broader impacts.
